 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...

CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference

Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial PerformanceFirst half 2023 total revenues with double-digit growth of 15.1% at 24.6 millionBoth...

CENTOGENE Reports First Half 2023 Financial Results

Results from pivotal study published in Diagnostics journalConfirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher diseaseCould predict clinical course of...

CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Centogene receives noncompliance notification from Nasdaq

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for August 2023. CENTOGENE representatives ...

CENTOGENE to Participate in Upcoming Conferences in August

Shares of Centogene (NASDAQ:CNTG  Get Free Report) traded up 1% during mid-day trading on Friday . The stock traded as high as $1.03 and last traded at $1.03. 15,079 shares were traded during mid-day trading, a decline of 98% from the average session volume of 883,209 shares. The stock had ...

Centogene (NASDAQ:CNTG) Stock Price Up 1%

Centogene (NASDAQ:CNTG Get Free Report) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 587,200 shares, a growth of 1,091.1% from the June 15th total of 49,300 shares. Currently, 5.0% of the shares of the stock are short sold. Based ...

Centogene (NASDAQ:CNTG) Short Interest Up 1,091.1% in June

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the Company), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received notifications from the Nasdaq Stock...

CENTOGENE Regains Compliance With Nasdaq Listing Requirements

Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment OptionsInclusion of 602 patients from 47 countries represents the worlds largest and most heterogeneous Niemann-Pick type C1 disease (NPC1) cohortStudy identified 287 unique ...

CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing...

Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

Watchers	1,124
52-Wk Low	$0.61
52-Wk High	$2.52

Market Cap	$31.46M
Volume (M)	21,972.00
52-Wk High	$2.52
52-Wk Low	$0.61

CNTG Centogene NV

About

Feed

News

Sentiment

Fundamentals